| abstract |
The present invention discloses isolated human monoclonal antibodies that bind to CD30 (such as human CD30). Such human antibodies can be produced in non-human transgenic animals, such as transgenic mice, capable of producing many isotypes of human monoclonal antibodies through V-D-J recombination and isotype conversion. In addition, treatment with derivatives of human antibodies (such as bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising such human antibodies, hybridomas capable of producing non-human transgenic animals and human antibodies and human antibodies as described above And diagnostic methods are also disclosed. |